Kenvue

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Kenvue (KVUE) reports strong Q2 earnings, eyes China growth

Kenvue's Q2 performance showcased robust net sales, organic growth, and strategic investments in key segments. The company's focus on consumer trust, supply chain enhancements, and capital allocation strategy underpin its resilience. Challenges include managing inflationary pressures and sustaining growth post-COVID, but opportunities in China and ongoing investments position Kenvue for future success.

Kenvue (KVUE) reports solid Q3 performance amidst segment challenges

Kenvue (KVUE) delivered a solid Q3 performance, showcasing strength in key segments despite challenges in others.
The company's strategic initiatives, focus on innovation, and outlook for growth opportunities position it well for future success.
Efforts to address challenges in specific segments and capitalize on opportunities demonstrate a proactive approach to sustaining growth and profitability.
Overall positive outlook on third-quarter results reflects the company's strong model, portfolio, and cash flow generation capabilities.

Kenvue reports mixed 2023 performance, focuses on growth strategies

Kenvue's 2023 performance saw organic growth but faced challenges in specific segments, leading to adjustments for 2024. The company aims to drive growth through operational efficiencies, increased brand investments, and a focus on consumer engagement. Challenges in U.S. in-store execution prompted a recovery plan and leadership changes.

Kenvue surpasses Q1 expectations, eyes China growth amid challenges

Kenvue's Q1 performance exceeded expectations, driven by key segments and brands.
Strategic focus on cost optimization, operational efficiency, and brand impact.
Challenges include stabilizing declining segments and managing hyperinflation impact.
Opportunities lie in growing China business, operational reinvention, and new leadership.

Kenvue reports solid Q2 performance and optimistic outlook for 2024

Kenvue's Q2 performance reflects steady growth and improved profitability, driven by strategic initiatives and strong brand performance. While cost management and increased marketing spend pose challenges, the company's focus on brand investment and long-term value creation offers promising opportunities for future growth and shareholder returns.

Kenvue reports Q3 growth, tackles Skin Health challenges, eyes savings

Kenvue's Q3 performance showed organic growth and strong financial metrics.
While facing challenges in the Skin Health segment, the company is focusing on recovery.
Investments in marketing and efficiency improvements highlight growth opportunities.
Executives addressed key questions on guidance, inventory levels, and growth strategies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kenvue, Inc. is a consumer health company. It operates through the following business segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care and hair, sun and others. The Essential Health segment focuses on oral care, baby care, women's health and wound care. The company was founded on February 23, 2022 and is headquartered in Skillman, NJ.

LOS ANGELES, CA / ACCESSWIRE / November 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Kenvue Inc. ("Kenvue" or "the Company") (NYSE:KVUE) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's May 2023 initial public offering ("IPO"), are encouraged to contact the firm before December 8, 2023.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Kenvue Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / November 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Kenvue Inc. ("Kenvue" or "the Company") (NYSE:KVUE) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's May 2023 initial public offering ("IPO"), are encouraged to contact the firm before December 8, 2023.

INVESTOR DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Kenvue Inc. with Losses of $100,000 to Contact the Firm

If you purchased or acquired securities in Kenvue securities pursuant and/or traceable to the registration statement and related prospectus (collectively, the "Registration Statement") issued in connection with the Company's May 2023 initial public offering (the "IPO" or "Offering") and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1310). You may also click here for additional information: http://www.faruqilaw.com/KVUE.

KENVUE SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Kenvue To Contact Him Directly To Discuss Their Options

LOS ANGELES, CA / ACCESSWIRE / November 17, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Kenvue Inc. ("Kenvue" or "the Company") (NYSE:KVUE) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's May 2023 initial public offering ("IPO"), are encouraged to contact the firm before December 8, 2023.

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Encourages Investors in Kenvue Inc. with Losses of $100,000 to Contact the Firm

RADNOR, Pa. , Nov. 16, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed against Kenvue Inc. ("Kenvue") (NYSE: KVUE).

Kessler Topaz Meltzer & Check, LLP Notifies Kenvue Inc. Investors of Securities Fraud Class Action Lawsuit Filed on Their Behalf

NEW YORK , Nov. 14, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Kenvue Inc. (NYSE: KVUE) pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with the Company's May 2023 initial public offering ("IPO" or the "Offering"), of the important December 8, 2023 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Kenvue securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LONGSTANDING LAW FIRM, Encourages Kenvue Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action Commenced by the Firm - KVUE

NEW YORK , Nov. 11, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Kenvue Inc. ("Kenvue" or the "Company") (NYSE: KVUE).   Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kenvue Inc. - KVUE

LOS ANGELES, CA / ACCESSWIRE / November 9, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Kenvue Inc. ("Kenvue" or "the Company") (NYSE:KVUE) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's May 2023 initial public offering ("IPO"), are encouraged to contact the firm before December 8, 2023.

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Kenvue Inc. with Losses of $100,000 to Contact the Firm

American Water Works

Kroger

MetLife

Merck

Procter & Gamble

At first glance, the proposal to dive into safe stocks to buy might appear overly conservative. As NPR recently pointed out, the U.S. GDP grew 4.9% in the third quarter, catalyzed by stronger-than-expected consumer spending.

7 Safe Stocks to Buy if You Think Q3's Gangbuster Growth Won't Last

RADNOR, Pa. , Nov. 7, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kenvue Inc. ("Kenvue") (NYSE: KVUE).

Kessler Topaz Meltzer & Check, LLP Reminds Kenvue Inc. Investors of Important Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors with Substantial Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / November 7, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Kenvue Inc. ("Kenvue" or "the Company") (NYSE:KVUE) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's May 2023 initial public offering ("IPO"), are encouraged to contact the firm before December 8, 2023.

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Kenvue Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , Nov. 6, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Kenvue Inc. (NYSE: KVUE) pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with the Company's May 2023 initial public offering ("IPO" or the "Offering"), of the important December 8, 2023 lead plaintiff deadline in the securities class action commenced by the Firm. SO WHAT: If you purchased Kenvue securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LEADING AND RANKED FIRM, Encourages Kenvue Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action Commenced by the Firm - KVUE

Alpha Technology Group Ltd

Bloomz Inc

Hamilton Insurance Group Ltd

Renaissance IPO ETF

Renaissance International IPO ETF

Lexeo Therapeutics Inc

Neo-Concept International Group Holdings Ltd

Pineapple Financial Inc

Palantir Technologies

Shimmick Corp

Waystar Holding Corp

Two IPOs are currently scheduled for the week ahead, although some small issuers may join the calendar late. As of 11/2/2023, the Renaissance IPO Index was up 23.5% year-to-date, while the S&P 500 was up 14.0%. Renaissance Capital's IPO ETF tracks Renaissance IPO Index, and top ETF holdings include Palantir Technologies and Kenvue.

U.S. IPO Weekly Recap: Biotech Lexeo Stumbles After $100 Million IPO

KENVUE SHAREHOLDER ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Kenvue To Contact Him Directly To Discuss Their Options

NEW YORK--(BUSINESS WIRE)---- $KVUE #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Kenvue Inc. (“Kenvue” or “the Company”) (NYSE: KVUE) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Kenvue securities pur.

KVUE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Kenvue Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Chevron

Waste Management

Anytime you bring up the concept of “forever stocks,” you're running the risk of incurring a serious tail risk. Obviously, forever is a long time – long enough for something to go wrong.

The 3 Best Forever Stocks to Buy in November

Kenvue stock pays a fairly high dividend that yields 4.4%. The company is expecting modest revenue growth of around 6% this year.

Can Kenvue Be a Reliable Dividend Stock to Hold for the Long Haul?

NEW YORK , Oct. 31, 2023 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Kenvue Inc. (NYSE: KVUE) pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with the Company's May 2023 initial public offering ("IPO" or the "Offering"), of the important December 8, 2023 lead plaintiff deadline. SO WHAT: If you purchased Kenvue securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Kenvue Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - KVUE

RADNOR, Pa. , Oct. 29, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed against Kenvue Inc. ("Kenvue") (NYSE: KVUE).

Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Kenvue Inc.

RADNOR, Pa.--(BUSINESS WIRE)-- #classaction--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey against Kenvue Inc. (“Kenvue”) (NYSE: KVUE). The action charges Kenvue with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Kenvue's.

KVUE Investor Announcement: Kessler Topaz Meltzer & Check, LLP Announces December 8, 2023 Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Filed Against Kenvue Inc. (KVUE)

Kenvue Inc (NYSE:KVUE ) Q3 2023 Earnings Conference Call October 26, 2023 8:30 AM ET Company Participants Tina Romani - Head of Investor Relations Thibaut Mongon - Chief Executive Officer and Director Paul Ruh - Chief Financial Officer Conference Call Participants Andrea Teixeira - JPMorgan Chase and Company Steve Powers - Deutsche Bank Jason English - Guggenheim Partners Anna Lizzul - Bank of America Merrill Lynch Filippo Falorni - Citi Susan Anderson - Canaccord Genuity Operator Greetings, and welcome to Kenvue's Third Quarter 2023 Earnings Conference Call. My name is Darryl, and I'll be your operator today.

Kenvue Inc. (KVUE) Q3 2023 Earnings Call Transcript

Haleon PLC

Sanofi

Sanofi (FRA: SNW), the giant healthcare company, is considering spinning off its consumer health business. In a statement, the management said it was hoping to create a separate company listed in France.

Sanofi to create its own Haleon, Kenvue as its stock price tumbles

Kenvue Inc's shares fell 1.7% in pre-market trading after the company posted in-line third-quarter earnings but tightened its full-year guidance after a slow start to the flu and cold season. The company, the former consumer health operations of Johnson & Johnson (NYSE:JNJ) posted net income of $438 million, or 23 cents a share, for the quarter, down from $586 million, or 34 cents a share, a year ago.

Kenvue shares lower amid slow start to cold and flu season

Kenvue Inc.'s stock KVUE, -1.25% fell 2.4% in premarket trade Thursday, after the company posted in-line third-quarter earnings but tightened its full-year guidance after a slow start to the flu and cold season. The company, the former consumer health operations of Johnson & Johnson JNJ, +0.22%, posted net income of $438 million, or 23 cents a share, for the quarter, down from $586 million, or 34 cents a share, in the year-earlier period.

Kenvue's stock slides premarket as company reports slow start to flu and cold season

Kenvue on Thursday reported higher third-quarter revenue, owing to strong demand for its self-care and skincare products such as Tylenol and Neutrogena.

News for Kenvue Stock (KVUE)